Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

Board

The Board of the Swiss Biotech Association is a working group of representatives from various Swiss biotech companies. It aims to support the biotech industry in Switzerland.

Dr. Dominik Escher

President
CDR-Life

Dominik Escher, Ph.D. is a biotechnology entrepreneur. He was a founder of ESBATech and was leading the company as CEO since its inception in 1998 until 2016. He raised more than USD 90 million venture capital for ESBATech. In 2009, ESBATech was acquired for USD 589 million by Alcon. Within Alcon Dominik continued to lead ESBATech and was Vice President of R&D Alcon and member of the group’s Global R&D Leadership Team.

In 2011, when Alcon was acquired by Novartis, ESBATech joined the Novartis Institutes of Biomedical Research (NIBR). As Head of ESBATech, a Novartis company, Dominik was a member of the NIBR Global Ophthalmology Leadership Team as well as the NIBR Global Leadership Team of Biologics.

At the same time as ESBATech was sold to Alcon, Dominik was a founder of Delenex Therapeutics. He served on the board of this biotech company until it was acquired by Cell Medica in 2016.

In 2017, Dominik founded CDR-Life, a new biotechnology company focusing on next generation biologics for therapeutic applications. He leads the company as Chairman.

Dominik obtained his Ph.D. from the University of Zurich. He also holds a Master of Science in Molecular Biology and Immunology from the University of Zurich and a Masters Degree in Education with specialization in Management and Organization from the ETH of Zurich.

Since 2002 he is a Board Member of the Swiss Biotech Association, the biotech industry organization of Switzerland which he leads as President since 2013.

Dr. Patrick Amstutz

Vice President
Molecular Partners

Dr. Patrick Amstutz is acting Chief Executive Officer of Molecular Partners AG in Schlieren. He co-founded Molecular Partners and has been a member of the Company’s management team since its inception in 2004. At the Company, Patrick has been responsible for business development, alliance management and research and development (R&D) operations. He has established a wide range of commercial collaborations and licensed several key technologies. Patrick holds a Master of Science from the ETH Zurich and a PhD in Molecular Biology from the University of Zurich.

Dr. Luca Bolliger

Vice President
Recordati

Luca Bolliger studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology. He graduated at the Biocenter in Basel in biochemistry, and then became Member of the Basel institute for immunology. He then joined the pharmaceutical industry as a Global discovery portfolio manager in the Pharma Strategy Unit at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management, and as a freelance consultant. He established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he was director Business Development.

Jurgi Camblong

Vice President
SOPHiA GENETICS

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz, and has since successfully been leading the development of the company, listed by the MIT Technology Review amongst the 50 smartest companies in 2017. Dr. Camblong is a member of the Advisory Council on Digital Transformation to the Swiss Federal Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.

Dr. Bettina Ernst

Vice President
Preclin Biosystems

Dr. Bettina Ernst has extensive experience working in fundamental immunology in Europe and the U.S., followed by working in the biotechnology and pharmaceutical industry. Dr. Ernst undertook a MBA, founded Preclin Biosystems and is responsible for operational management and business development.

Dr. Ulf Grawunder

Vice President
NBE-Therapeutics

Ulf Grawunder is an experienced Swiss Life-Science entrepreneur with over 10 years experience in the therapeutic antibody development industry. With NBE-Therapeutics, he has recently founded his second Swiss Biotech company and is leading NBE-Therapeutics as its CEO since June 2012. 
Ulf Grawunder has invented two new patent-pending technologies at NBE-Therapeutics that allow the company to develop most highly innovative antibody-based drugs, including next-generation antibody drug conjugates (ADCs) for the therapy of cancer. Before that, Ulf Grawunder co-founded the Swiss Biotech company 4-Antibody, recently sold to U.S.-based Agenus (AGEN), where since 2004 he served as founding CEO and after 2006 assumed the role of CSO. During his tenure at 4-Antibody, Ulf Grawunder raised about CHF 50 million capital for the company, secured two pharma/biotech collaborations with Boehringer Ingelheim, Germany, and Human Genome Sciences, U.S.A. and grew the company to 50 employees.
 Ulf Grawunder is serving on various Boards of non-profit and for-profit life-science organizations and is vice-president and Board member of the Swiss Biotech Association. Ulf Grawunder holds a PhD in Cell Biology from the University of Basel, for work on early B cell development performed at the Basel Institute for Immunology. In addition, Ulf Grawunder holds a Diploma in Technology Entrepreneurship from the Entrepreneur and Business School in St. Gallen, Switzerland (HSG=Hochschule St. Gallen).

Martin Howald

Vice President and Honorary Member
BioConcept

Filippo Riva

Vice President
Humabs Biomed

Filippo Riva, MBA, is CEO and CFO of Humabs Biomed SA in Bellinzona. He brings over 15 years management experience in both privately held and venture backed biotech and high-tech companies. Filippo holds a degree in Economics from the School of Economics and Business Administration of Lugano and a MBA from the Warwick Business School, United Kingdom.

Team


Michael Altorfer

CEO
Swiss Biotech Association


Heike Bihlmann

Liaison Basel Area
Swiss Biotech Association


Sabine Bamert

Communications
Swiss Biotech Association


Marta Gehring

Liaison Suisse Romande
Swiss Biotech Association


Cathy Kroll

Special projects
Swiss Biotech Association


Gabriela Luternauer

Administration & Member support
Swiss Biotech Association

Honorary members

Domenico Alexakis

Former CEO and HM since 2017
Bridge Plus AG

Adrian Härri

HM since 2017
Biolytix AG

Dr. Herbert Reutimann

HM since 2005
Unitectra AG

Dr. Roland P. Bühlmann

HM since 2005
BÜHLMANN Laboratories AG

Prof. Dr. Oreste Ghisalba †

President
Was HM since 1997

Deeply moved and saddened, we have to say goodbye to our long-time Vice President and Honorary Member.

Prof. Dr. Oreste Ghisalba-Roos

who passed away much too early on December 4, 2018.

With Oreste Ghisalba we lose a friend, colleague and committed pioneer of biotechnological research and development in Switzerland. In 1998, Oreste Ghisalba, a founding member of the Swiss Biotech Association, laid the foundation stone for the Swiss Biotech Association.

For more than 20 years, Oreste Ghisalba was a driving force in the development of our industry association and its Vice President from 2005-2017. As Professor of Biotechnology at the University of Basel, member of the Advisory Board of the Swiss Academies of Science and Technology (SATW) and of the Commission for the Coordination of Biotechnology (SKB), Oreste Ghisalba has been committed to Swiss research and biotechnological research. As Head of the Biotechnology Division of the Commission for Technology and Innovation, Oreste Ghisalba has also evaluated and promoted cooperation between universities and biotechnology companies for many years.

In 2017, the Swiss Biotech Association appointed Oreste Ghisalba as an Honorary Member in recognition of his years of commitment to strengthening biotechnology in Switzerland.
We will miss Oreste Ghisalba very much and keep him in our memory.

Our deepest sympathy goes to the mourning family, to whom we wish much strength and support in these difficult times.


Swiss Biotech Association